Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

3668 - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit.

Date

09 Sep 2017

Session

Head and neck cancer, excluding thyroid

Presenters

Cecile Mertens

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

C. Mertens1, H. Le Caer2, C. Ortholan3, E. Blot4, C. Even5, H. Rousselot6, F. Peyrade7, C. Sire8, D. Cupissol9, Y. Pointreau10, P. Debourdeau11, F. Rolland12, J. Fayette13, O. Capitain14, X. Sun15, M. Debbah5, D. Schwob16, R. Boulahssass17, A. Aupérin5, J. Guigay18

Author affiliations

  • 1 Oncology, Institut Bergonié, 33000 - Bordeaux/FR
  • 2 Oncology, Hospital, Saint Brieuc/FR
  • 3 Radiotherapy, Princess Grace Hospital, Monaco/MC
  • 4 Oncology, Centre d'Oncologie St. Yves, 56000 - Vannes/FR
  • 5 Oncology Medical, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 6 Gerontology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy/FR
  • 7 Onco-hematology, Centre Antoine Lacassagne, 06100 - Nice/FR
  • 8 Radiotherapy, Hôpital Bretagne Sud, Lorient/FR
  • 9 Oncology, Institut régional du Cancer de Montpellier, Montpellier/FR
  • 10 Oncology, Centre Jean Bernard et Clinique Victor Hugo, Le Mans/FR
  • 11 Oncology, Institut Sainte Catherine, Avignon/FR
  • 12 Oncology, Centre de Cancérologie René Gauducheau, Saint-Herblain/FR
  • 13 Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 14 Oncology, Centre Paul Papin, 49100 - Angers/FR
  • 15 Radiothérapy, Hopital du nord franche comté ( HNFC) & CHRU Besançon, 25209 - Montbéliard & Besançon/FR
  • 16 Oncology Research, Gustave Roussy, Villejuif/FR
  • 17 Gerontology, CHU de Nice, Nice/FR
  • 18 Department Of Medical Oncology, Centre Antoine Lacassagne, Nice/FR
More

Resources

Abstract 3668

Background

About 47% and 10% of head and neck squamous cell carcinomas (HNSCC) occur in patients (pts) aged 65+ or 80+ respectively. This population being heterogeneous, balancing efficacy with toxicity is challenging.

Methods

ONCOVAL is the first step of the ELAN program for pts 70+ with HNSCC, not amenable to surgery. During ONCOVAL, pts were assessed for frailty before inclusion to appropriate trial depending on curative or palliative setting and fit or unfit status. The primary aim was to evaluate whether a suited geriatric evaluation (SGE) for use by oncologist is feasible to stratify pts as fit or unfit. The SGE was elaborated by GERICO (French UNICANCER group dedicated to clinical research in elderly cancer pts) specifically for HNSCC pts, derived from the comprehensive geriatric assessment (CGA) and evaluating functional status, comorbidity, cognition, mental health status, social status, nutrition. Full CGA performed by geriatricians was optional.

Results

Between 06/2013 and 02/2017, 495 pts were included in 42 centers. Data available for 463 pts. Median age 79 years (70-95) with 46% over 80. 74% males. 67% of SGE was performed by oncologists and 33% by nurses/clinical research staff. Mean time to complete SGE was 22 minutes. After SGE, 72% pts were classified as unfit. 52% of pts were further assessed by CGA, 48% among SGE fit pts and 53% among SGE unfit pts. Concordance rate of classification Unfit/Fit by SGE and CGA was 81%. Among pts planned to be treated by curative radiotherapy (RT) or chemo(CT)-RT after oncologic evaluation alone, the planned treatment changed after SGE for 8% of pts: addition of CT/biotherapy to RT for 4% or deletion of CT for 4%. Rate of pts requiring multidisciplinary interventions was significantly higher when the assessment was also performed by geriatricians (71% vs 51%), even after adjusting for frailty.

Conclusions

A CGA-based SGE for use by oncologist in older pts with HNSCC seems feasible and is a first necessary step to define optimal care. Oncologists and geriatricians must keep going developing such close collaboration and data sharing before proposing tailored treatment.

Clinical trial identification

Legal entity responsible for the study

Gustave Roussy

Funding

INCa (National Institut of Cancer), ARC, Ligue Nationale Contre le Cancer

Disclosure

H. Le Caer: Grant/: research: Roche. C. Even: Advisory/Board Member: Bristol-Myers Squibb, AstraZeneca, Merck Serrono, MSD, Innate Pharma. F. Peyrade: Advisory board: Board ORL Merck France. Y. Pointreau: Advisory/Board Member: Bristol-Myers Squibb; Honoraria: Bristol-Myers Squibb, MSD. P. Debourdeau: Advisory/Board Member: Pfizer. J. Fayette: Advisory/Board Member: Bristol-Myers Squibb, Honoraria: Bristol-Myers Squibb, AstraZeneca. R. Boulahssass: Advisory/Board Member: Teva Honoraria: Nutricia, Roche, Teva, Novartis, Pierre Fabre, Amgen, takeda, Kephren. J. Guigay: Advisory board: AstraZeneca; Bristol-Myers Squib, Innate Pharma, Merck serono Grant/: research: Bristol-Myers Squibb, Chugai, Gsk, Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.